Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: GLP-1 Receptor Agonist Treatment Clear all

Conditions: Alcohol Use Disorder (AUD)
Interventions: Pemvidutide, Placebo; Drug · Other
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 12
States / cities: Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 9 more

Conditions: Endometrial Cancer
Interventions: Tirzepatide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Obesity
Interventions: Biometric-informed care, Control Arm: Standard Care; Behavioral
Lead sponsor: Jeff Reeves; Other
Eligibility: 18 Years to 64 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: San Diego, California

Conditions: GLP-1 Receptor Agonist Treatment
Interventions: GLP-1 Receptor Agonists; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 25,505 participants
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Pediatric Obesity, Obesity
Interventions: Semaglutide; Drug
Lead sponsor: Erin Mauney; Other
Eligibility: 12 Years to 15 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes
Interventions: protein supplement; Dietary Supplement
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Body Composition
Interventions: Smartwatch activity and body composition monitor, General guidance on recommended exercise; Device · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 99 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders, Chemically-Induced Disorders, Mental Disorder, Opioid
Interventions: Semaglutide Pen Injector, Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Baltimore, Maryland • Fall River, Massachusetts • New York, New York + 1 more

Conditions: Overweight and Obesity, Healthy
Interventions: NG101, Placebo, Semaglutide Injectable Product; Drug
Lead sponsor: Neurogastrx, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Obesity, Overweight, or Chronic Weight Management
Interventions: aleniglipron or placebo; Drug
Lead sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 11
States / cities: Phoenix, Arizona • Chicago, Illinois • Richfield, Minnesota + 8 more

Conditions: Obesity, Skeletal Muscle, Brain Connectivity
Interventions: Exercise training, Semaglutide, Therapy Cessation; Behavioral · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 50 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Autosomal Dominant Polycystic Kidney, Obesity
Interventions: Tirzepatide, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Obesity, Aging
Interventions: Semaglutide Pen Injector; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 65 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: Lixisenatide (AVE0010), Placebo, Basal Insulin, Metformin, Pen auto-injector; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Obesity, Overweight, or Chronic Weight Management
Interventions: Aleniglipron or Placebo, Aleniglipron; Drug
Lead sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 39
States / cities: Phoenix, Arizona • Anaheim, California • Los Angeles, California + 33 more

Conditions: Alcohol Use Disorder
Interventions: Exenatide, Sham injection; Drug · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 21 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Spinal Cord Injuries, Type 2 Diabetes
Interventions: Semaglutide Injectable Product, Placebo; Drug · Other
Lead sponsor: Marzieh Salehi; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Laxity; Skin
Interventions: On GLP1 plus HRT, On GLP1 Only; Drug
Lead sponsor: Goldman, Butterwick, Fitzpatrick and Groff; Other
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Diego, California

Conditions: Diabetes Mellitus Type 2
Interventions: Lixisenatide (AVE0010), Placebo, Pen auto-injector, Pioglitazone, Metformin; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 85
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 72 more

Conditions: Obesity & Overweight, Mobility Disability, HOMA-IR
Interventions: Enobosarm, Semaglutide (Wegovy) weekly injection; Drug
Lead sponsor: Veru Inc.; Industry
Eligibility: 65 Years to 100 Years
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 13
States / cities: Phoenix, Arizona • Doral, Florida • Miami, Florida + 7 more

Conditions: Diabetes Mellitus
Interventions: Albiglutide 30 mg, Albiglutide 50 mg, Albiglutide matching placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 9,463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 146
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 125 more

Conditions: Diabetes Mellitus, Type 2
Interventions: IcoSema, Semaglutide 1 mg; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 683 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 76
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 65 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Albiglutide, Insulin Glargine and Insulin Lispro; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 814 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 39
States / cities: Searcy, Arkansas • Huntington Beach, California • Long Beach, California + 34 more

Conditions: Prostate Carcinoma, Recurrent Prostate Carcinoma
Interventions: Antiandrogen Therapy, Behavioral Intervention, Biospecimen Collection, Cardiac Computerized Tomographic Angiography, Computed Tomography, Electronic Health Record Review, Internet-Based Intervention, Lifestyle Counseling, Medical Device Usage and Evaluation, Nutritional Intervention, Questionnaire Administration, Radiation Therapy, Referral, Semaglutide, Short-Term Fasting, Tirzepatide; Drug · Behavioral · Procedure + 2 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 30 Years to 79 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Duarte, California

Search by objective public record fields.

RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

A Study of a Weight Loss Intervention in People With Endometrial Cancer

Continuous Wearable Biometric Monitoring in Adults Undergoing Obesity Treatment (SMART-BMI)

GLP-1 Receptor Agonists in the Surgical Patient: Prevalence, Epidemiology, and Pulmonary Complications

Brain and Obesity Longitudinal Development: Neurobiological Mechanisms of Semaglutide Treatment of Adolescent Obesity

Nutrition+: Effect of a High-Protein Diabetes Formula on Body Composition in Type 2 Diabetes Patients Treated With Incretin Mimetics

Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment

GLP-1R Agonist Treatment for Opioid Use Disorder

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist

Aleniglipron Phase 2 Body Composition Study

Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity

Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

Semaglutide Use in Elderly Obese Patients

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin

A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers

Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes

Evaluate the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement Therapy Taking Glucagon-like Peptide-1 Agonist

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone

Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)

Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial